Lexagene Holdings (Lexagene Holdings) Interest Expense : $-0.07 Mil (TTM As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lexagene Holdings's interest expense for the three months ended in Nov. 2022 was $ -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Nov. 2022 was $-0.07 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lexagene Holdings's Operating Income for the three months ended in Nov. 2022 was $ -1.66 Mil. Lexagene Holdings's Interest Expense for the three months ended in Nov. 2022 was $ -0.02 Mil. Lexagene Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lexagene Holdings Interest Expense Historical Data

The historical data trend for Lexagene Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Interest Expense Chart

Lexagene Holdings Annual Data

Trend

Mar13

Mar14

Mar15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Interest Expense

Get a 7-Day Free Trial

-0.10

-0.08

-0.07

Lexagene Holdings Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Interest Expense	Get a 7-Day Free Trial															-0.02	-0.02	-0.02	-0.01	-0.02

Lexagene Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07 Mil.

Lexagene Holdings (OTCPK:LXXGQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lexagene Holdings's Interest Expense for the three months ended in Nov. 2022 was $-0.02 Mil. Its Operating Income for the three months ended in Nov. 2022 was $-1.66 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Nov. 2022 was $0.56 Mil.

Lexagene Holdings's Interest Coverage for the quarter that ended in Nov. 2022 is calculated as

Lexagene Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Lexagene Holdings (Lexagene Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915

Website

https://www.lexagene.com

Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.